{
  "symbol": "CPRX",
  "company_name": "Catalyst Pharm Inc",
  "ir_website": "https://ir.catalystpharma.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List",
          "url": "https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-recognized-one-north-americas-fastest",
          "content": "[Skip to content](#lfg-main-content)\n\n  * [•](https://catalystpharma.com/)\n  * [Follow Us:](#)\n  * [ ![Facebook](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/facebook-xl.png) ](https://www.facebook.com/CatalystForRare)\n  * [ ![Twitter](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/twitter-xl.png) ](https://twitter.com/CatalystForRare)\n  * [ ![Linkedin](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/linkedin-6-xl.png) ](https://www.linkedin.com/company/catalystforrare)\n  * [**Grant Portal**](https://catalystpharma.secure.force.com/fundingrequest/)\n\n\n\n[ ![Catalystpharma.com](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/Catalyst_logo_color.svg) ](https://catalystpharma.com/)\n\nSelect Page\n\n  * [ About Catalyst](http://catalystpharma.com/about-catalyst/)\n    * [History](http://catalystpharma.com/history/)\n    * [Management](http://catalystpharma.com/management/)\n    * [Board Of Directors](http://catalystpharma.com/board-of-directors/)\n    * [Events and Presentations](/events-and-presentations)\n    * [Careers](http://catalystpharma.com/careers/)\n    * [Contact Us](http://catalystpharma.com/contact-us/)\n  * [ Patient Focus](https://catalystpharma.com/patient-focus/)\n    * [ Patient Stories](http://catalystpharma.com/patient-stories/)\n      * [LEMS Stories](http://catalystpharma.com/lems-stories/)\n    * [ Disease Information](http://catalystpharma.com/disease-information/)\n      * [LEMS](http://catalystpharma.com/lems/)\n      * [MuSK-MG](http://catalystpharma.com/musk-mg/)\n      * [Duchenne Muscular Dystrophy (DMD)](https://catalystpharma.com/duchenne-muscular-dystrophy-dmd/)\n    * [ Patient Resources](http://catalystpharma.com/community-engagement/)\n      * [Organizations](https://catalystpharma.com/organizations/)\n      * [Event Calendar](https://catalystpharma.com/event-calendar/)\n      * [Patient Engagement](https://catalystpharma.com/patient-engagement/)\n  * [ Research & Pipeline](http://catalystpharma.com/research-pipeline/)\n    * [Roadmap To Success (Strategy)](http://catalystpharma.com/roadmap-to-success-strategy/)\n    * [ Pipeline (clinical)](http://catalystpharma.com/pipeline-clinical/)\n      * [LEMS Clinical](http://catalystpharma.com/lems-clinical/)\n    * [Business Development](http://catalystpharma.com/business-development/)\n    * [Healthcare Professional Outreach](https://catalystpharma.com/healthcare-professional-outreach/)\n    * [Clinical Trials](https://catalystpharma.com/clinical-trials/)\n  * [ Products](http://catalystpharma.com/amifampridine-phosphate/)\n    * [APPROVED PRODUCTS](https://catalystpharma.com/products/)\n  * [ ESG Responsibility](http://catalystpharma.com/responsibility/)\n    * [Corporate Giving](http://catalystpharma.com/corporate-giving/)\n    * [Investigator Sponsored Research](http://catalystpharma.com/investigator-sponsored-research/)\n    * [ ESG Report](https://catalystpharma.com/responsibility/esg/)\n      * [ESG SASB DISCLOSURE](https://catalystpharma.com/wp-content/uploads/2022/06/Catalyst-SASB-Index_5.25.22_FINAL.pdf)\n  * [ Investors](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-and-presentations)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [ Corporate Governance](/corporate-governance/governance-overview)\n      * [Documents & Charters ](/corporate-governance/governance-overview)\n      * [Board of Directors](https://catalystpharma.com/board-of-directors/)\n      * [Management](https://catalystpharma.com/management/)\n      * [Committee Composition](/corporate-governance/committee-composition)\n      * [Board Diversity Matrix ](/board-diversity-matrix-1)\n      * [Contact the Board](/corporate-governance/governance-contacts)\n    * [ Stock Information](/stock-information)\n      * [Stock Information](/stock-information)\n      * [Historic Stock Lookup](/stock-information/historic-stock-lookup)\n    * [Annual Report and Proxy](/financial-information/annual-reports)\n    * [Analyst Coverage](/financial-information/analyst-coverage)\n    * [Email Alerts](/shareholder-services/email-alerts)\n  * [•](https://catalystpharma.com/)\n  * [Follow Us:](#)\n  * [ ![Facebook](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/facebook-xl.png) ](https://www.facebook.com/CatalystForRare)\n  * [ ![Twitter](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/twitter-xl.png) ](https://twitter.com/CatalystForRare)\n  * [ ![Linkedin](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/linkedin-6-xl.png) ](https://www.linkedin.com/company/catalystforrare)\n  * [**Grant Portal**](https://catalystpharma.secure.force.com/fundingrequest/)\n\n\n\n#  Press Releases \n\nInvestor Menu\n\n## \n\nCatalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List\n\nNovember 25, 2024 at 8:03 AM EST\n\n_Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution_\n\nCORAL GABLES, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (\"Catalyst\" or \"Company\") (Nasdaq: CPRX), today announced it ranked number 452 on the [Deloitte Technology Fast 500](https://www.globenewswire.com/Tracker?data=DD8iNQorOG2XWnBT8KXPZUhSBUYGAWz2koyBENnfutdJw8Gcz08WbzleJx06TOhV60luKrNao4z1Add5NhfEAKpEXl_3gBkvoh_z3AqSOyNjhLx8w9OkCSzGUykQPf6O71PY2n-HGMLH5FRKM0BQLnFALqpJv9mSY1vmd92MncJHFFHKAxHOrwgerO7VPdhkHg4LujP72B26V0wuAENH4AM9Koa2ZTbUZVtUcavAPmI=)™, a ranking of the 500 fastest-growing technology media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. The 2024 Deloitte Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023, for which Catalyst grew 234% during this period.\n\nCatalyst’s President and Chief Executive Officer, Richard J. Daly, credits the team’s operational excellence and strong commercial execution for the 234% revenue growth. He said, “It's an honor to be recognized as one of the fastest-growing companies in North America across industry sectors. We remain confident in our ability to execute against our strategy, which includes capitalizing on new opportunities to broaden our rare orphan portfolio with innovative and differentiated products, and we remain steadfast in enhancing our growth potential while prioritizing the needs of our patient communities.”\n\n“For 30 years we’ve been celebrating companies that are actively driving innovation. The software industry continues to be a beacon of growth, and the fintech industry made a strong showing on this year’s list, surpassing life sciences for the first time,” said [Steve Fineberg](https://www.globenewswire.com/Tracker?data=lcieQo5l976zPUo8HGx8ECM_tKe4fW4Qg6e-Qc1DgGuH_4DFXDo2raaKMLF51wW3D-fZMmYUg1JbZiGLaiGCxEu3wLNpcxjzbkzCQrZP-DtnsXH5bFEwbQ8z18t528gN92JqafphtYnh1blimqyzUA==), Vice Chair, U.S. technology sector leader, Deloitte. “Significantly, we also saw a breakthrough in performance of private companies, with the highest number of private companies named to the list in our program’s history. This year’s winners have shown they have the vision and expertise to continue to perform at a high level, and that deserves to be celebrated.”\n\n“Innovation, transformation and disruption of the status quo are at the forefront for this year’s Technology Fast 500 list, and there’s no better way to celebrate 30 years of program history,” said [Christie Simons](https://www.globenewswire.com/Tracker?data=bb2Xw-FXis0dMO292CvKN0dpy5GNX-T_L3MyC0DAfOGWxVmOKfuoN-QrGMrBtqH5eDXkh_6ybit7Ue2GsnK1rvY7e_TH7H4WsMuatjXzwKciK3B3eSko4WvGnJ228ixwamyQsB5m1Lju4DvPgNZl_w==), Partner, Deloitte & Touche LLP and industry leader for technology, media and telecommunications within Deloitte’s Audit & Assurance practice. “This year’s winning companies have demonstrated a continuous commitment to growth and remarkable consistency in driving forward progress. We extend our congratulations to all of this year’s winners — it’s an incredible time for innovation.”\n\nOverall, 2024 Technology Fast 500 companies achieved revenue growth ranging from 201% to 153,625% over the three-year time frame, with an average growth rate of 1,981% and median growth rate of 460%.\n\n**About the 2024 Deloitte Technology Fast 500** Now in its 30th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023.\n\nIn order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US $50,000, and current-year operating revenues of at least US $5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.\n\n**About Catalyst Pharmaceuticals** Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst is headquartered in Coral Gables, FL., and was recognized on the Forbes 2024 list as one of America's most successful small-cap companies.\n\nFor more information, please visit Catalyst's website at [www.catalystpharma.com](https://www.globenewswire.com/Tracker?data=QRlGod_7La8C7UeUSk5q1dJdo6cm2-Z0o5CYSTiQwd9cf4LiZ3dZsnX19BjxcZxLJTtcaJiPRnpgoLjNRo9OVZo_TZKnZOq7xT0eCZMTz3g=).\n\n**About Deloitte** Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world’s most admired brands, including nearly 90% of the Fortune 500® and more than 8,500 U.S.-based private companies. At Deloitte, we strive to live our purpose of making an [impact that matters](https://www.globenewswire.com/Tracker?data=r-M1KJTOtfvR2_jW4EOs2j76M6V2E3zYxP51rwFSOBPnfw9yPkpbti6BBFH0xB3TmRoPqNLsGC_Z9ncWSf0kj1-1hGOj6j8I3v5QHARjoU5gYhRoS4bPk064ZfpcQ1m5JYqi0oMFcUrjjPkbQRxUaO1MyV7ylG0w6FwCrUHr1BM3vX3jlW9P5wGZbO8ow8Lu) by creating trust and confidence in a more equitable society. We leverage our unique blend of business acumen, command of technology, and strategic technology alliances to advise our clients across industries as they [build their future](https://www.globenewswire.com/Tracker?data=IXUDD3sBhBghnEtXvIocVC3VeHtphtK-HFjMAUfiI4hnFqlbUwuc1lraJdXS--Od6qY7oVyHzAT4pDXi4ubmhmDJ9uIcjhCswZsR-lf2L3tpgit2MlWWis8vlp69zZVBEq2PR0ybPyf8RoL37aflzcEb13tv8tKxdKzAJHUvxKtHzv2GYKhvLz0PIgrZct925DzJTK4jZZTCG5pyiMqHBQ==). Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Bringing more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte’s approximately 460,000 people worldwide connect for impact at [www.deloitte.com](https://www.globenewswire.com/Tracker?data=OYiOs3qNBer6_PWse2vFE7jD3uETBog4bWvH0lwJQqrLl_KbqD2GgGSfVoYmj9F23ijFzXVZObhKLCamEilp2g==).\n\n**Forward-Looking Statements** This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission (\"SEC\"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.\n\nSource: Catalyst Pharmaceuticals, Inc.\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI4OTIxMSM2NjA4NjI0IzIwMTk0OTE=)\n\n![](https://ml.globenewswire.com/media/NThjNmY0NGMtZjViZS00YWIwLWI4ZDItZDNlOWMwODgzOGIwLTEwMzEwMzE=/tiny/Catalyst-Pharmaceuticals-Inc-.png)\n\n```\nInvestor Contact Mary Coleman, Catalyst Pharmaceuticals, Inc. (305) 420-3200 mcoleman@catalystpharma.com Media Contact David Schull, Russo Partners (858) 717-2310 david.schull@russopartnersllc.com\n```\n\n[![Primary Logo](https://ml.globenewswire.com/media/960a6989-9f9c-4ad2-91cf-be10cebd6655/small/catalyst-pharmaceutical-logo.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/960a6989-9f9c-4ad2-91cf-be10cebd6655)\n\nSource: Catalyst Pharmaceuticals, Inc.\n\n  * [ Email Alerts ](/shareholder-services/email-alerts \"Email Alerts\")\n  * [ RSS ](/rss \"RSS\")\n  * [ Print page ](javascript:window.print\\(\\); \"Print this Page\")\n  * [ Search ](/search \"Search\")\n\n\n"
        },
        {
          "title": "Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences",
          "url": "https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-participate-upcoming-investor-0",
          "content": "[Skip to content](#lfg-main-content)\n\n  * [•](https://catalystpharma.com/)\n  * [Follow Us:](#)\n  * [ ![Facebook](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/facebook-xl.png) ](https://www.facebook.com/CatalystForRare)\n  * [ ![Twitter](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/twitter-xl.png) ](https://twitter.com/CatalystForRare)\n  * [ ![Linkedin](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/linkedin-6-xl.png) ](https://www.linkedin.com/company/catalystforrare)\n  * [**Grant Portal**](https://catalystpharma.secure.force.com/fundingrequest/)\n\n\n\n[ ![Catalystpharma.com](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/Catalyst_logo_color.svg) ](https://catalystpharma.com/)\n\nSelect Page\n\n  * [ About Catalyst](http://catalystpharma.com/about-catalyst/)\n    * [History](http://catalystpharma.com/history/)\n    * [Management](http://catalystpharma.com/management/)\n    * [Board Of Directors](http://catalystpharma.com/board-of-directors/)\n    * [Events and Presentations](/events-and-presentations)\n    * [Careers](http://catalystpharma.com/careers/)\n    * [Contact Us](http://catalystpharma.com/contact-us/)\n  * [ Patient Focus](https://catalystpharma.com/patient-focus/)\n    * [ Patient Stories](http://catalystpharma.com/patient-stories/)\n      * [LEMS Stories](http://catalystpharma.com/lems-stories/)\n    * [ Disease Information](http://catalystpharma.com/disease-information/)\n      * [LEMS](http://catalystpharma.com/lems/)\n      * [MuSK-MG](http://catalystpharma.com/musk-mg/)\n      * [Duchenne Muscular Dystrophy (DMD)](https://catalystpharma.com/duchenne-muscular-dystrophy-dmd/)\n    * [ Patient Resources](http://catalystpharma.com/community-engagement/)\n      * [Organizations](https://catalystpharma.com/organizations/)\n      * [Event Calendar](https://catalystpharma.com/event-calendar/)\n      * [Patient Engagement](https://catalystpharma.com/patient-engagement/)\n  * [ Research & Pipeline](http://catalystpharma.com/research-pipeline/)\n    * [Roadmap To Success (Strategy)](http://catalystpharma.com/roadmap-to-success-strategy/)\n    * [ Pipeline (clinical)](http://catalystpharma.com/pipeline-clinical/)\n      * [LEMS Clinical](http://catalystpharma.com/lems-clinical/)\n    * [Business Development](http://catalystpharma.com/business-development/)\n    * [Healthcare Professional Outreach](https://catalystpharma.com/healthcare-professional-outreach/)\n    * [Clinical Trials](https://catalystpharma.com/clinical-trials/)\n  * [ Products](http://catalystpharma.com/amifampridine-phosphate/)\n    * [APPROVED PRODUCTS](https://catalystpharma.com/products/)\n  * [ ESG Responsibility](http://catalystpharma.com/responsibility/)\n    * [Corporate Giving](http://catalystpharma.com/corporate-giving/)\n    * [Investigator Sponsored Research](http://catalystpharma.com/investigator-sponsored-research/)\n    * [ ESG Report](https://catalystpharma.com/responsibility/esg/)\n      * [ESG SASB DISCLOSURE](https://catalystpharma.com/wp-content/uploads/2022/06/Catalyst-SASB-Index_5.25.22_FINAL.pdf)\n  * [ Investors](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-and-presentations)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [ Corporate Governance](/corporate-governance/governance-overview)\n      * [Documents & Charters ](/corporate-governance/governance-overview)\n      * [Board of Directors](https://catalystpharma.com/board-of-directors/)\n      * [Management](https://catalystpharma.com/management/)\n      * [Committee Composition](/corporate-governance/committee-composition)\n      * [Board Diversity Matrix ](/board-diversity-matrix-1)\n      * [Contact the Board](/corporate-governance/governance-contacts)\n    * [ Stock Information](/stock-information)\n      * [Stock Information](/stock-information)\n      * [Historic Stock Lookup](/stock-information/historic-stock-lookup)\n    * [Annual Report and Proxy](/financial-information/annual-reports)\n    * [Analyst Coverage](/financial-information/analyst-coverage)\n    * [Email Alerts](/shareholder-services/email-alerts)\n  * [•](https://catalystpharma.com/)\n  * [Follow Us:](#)\n  * [ ![Facebook](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/facebook-xl.png) ](https://www.facebook.com/CatalystForRare)\n  * [ ![Twitter](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/twitter-xl.png) ](https://twitter.com/CatalystForRare)\n  * [ ![Linkedin](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/linkedin-6-xl.png) ](https://www.linkedin.com/company/catalystforrare)\n  * [**Grant Portal**](https://catalystpharma.secure.force.com/fundingrequest/)\n\n\n\n#  Press Releases \n\nInvestor Menu\n\n## \n\nCatalyst Pharmaceuticals to Participate in Upcoming Investor Conferences\n\nNovember 19, 2024 at 8:03 AM EST\n\nCORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (\"Catalyst\" or \"Company\") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below.\n\n**Piper Sandler 36th Annual Healthcare Conference****Date:** Tuesday, December 3, 2024**Presentation:** 2:00 PM ET[**Webcast Link**](https://www.globenewswire.com/Tracker?data=kfcQRjL2Cr9afxT_mklBXy5djNz-WmNwWoYA2lhH-zgq8-HbGM7rnoKmdkOfSZN7qyLgg5IXwroCAHIJu8rwtmOxjtlyvJJBAgHhinwEtDyh27XNF-jfwFcKn1aglV64L7adz_nLxWR44rPJmR3KiQ==)\n\n**Citi's 2024 Global Healthcare Conference****Date:** Wednesday, December 4, 2024**Presentation:** 1:00 PM ET[**Webcast Link**](https://www.globenewswire.com/Tracker?data=kfcQRjL2Cr9afxT_mklBXzqU_ek5LYCNgkzZ2Vl462gt3FQ5QcXVBcDsdgZ-Kv693ADmbbP11Nv6WcsFC-AVDg_8tIQ4mcj1BkFP_ArVO-BD0qq-Ma9v6JL-b-KK6OPaTE0nEpgG2hb9ZtNPZbZC28b01YfPlZmQrUv6UklLxDE=)\n\nThe webcasts will be available under the Investors section on the Company's website, [www.catalystpharma.com](https://www.globenewswire.com/Tracker?data=jFwSpJfMYI0jix4PmRCKJZMzPPACMB1GAhU6JKeWE7fQgK3pMjtjErFm11PbyE9cd1Fl0SXyqIXEE14lfXVQy2tZyl5g55tezHy9M9ZDy2g=), and a replay will be available for at least 30 days.\n\n**About Catalyst Pharmaceuticals** Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst is headquartered in Coral Gables, FL., and was recognized on the Forbes 2024 list as one of America's most successful small-cap companies.\n\nFor more information, please visit Catalyst's website at [www.catalystpharma.com](https://www.globenewswire.com/Tracker?data=jFwSpJfMYI0jix4PmRCKJZMzPPACMB1GAhU6JKeWE7e2lUey5F0JZg55eNAdktsWcK8VFtKm1PBXj_Kb3_57q-bfViY5C30tPVuSCH_1eXc=).\n\n**Forward-Looking Statements** This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission (\"SEC\"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.\n\nSource: Catalyst Pharmaceuticals, Inc.\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI3NTY1OCM2NTg4NDkxIzIwMTk0OTE=)![](https://ml.globenewswire.com/media/ZTU4MDllY2QtNDlmYi00NmEwLWIxZmUtMGRmODY1NjY3NDNhLTEwMzEwMzE=/tiny/Catalyst-Pharmaceuticals-Inc-.png)```\nInvestor Contact Mary Coleman, Catalyst Pharmaceuticals, Inc. (305) 420-3200 mcoleman@catalystpharma.com Media Contact David Schull, Russo Partners (858) 717-2310 david.schull@russopartnersllc.com\n```\n\n[![Primary Logo](https://ml.globenewswire.com/media/960a6989-9f9c-4ad2-91cf-be10cebd6655/small/catalyst-pharmaceutical-logo.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/960a6989-9f9c-4ad2-91cf-be10cebd6655)\n\nSource: Catalyst Pharmaceuticals, Inc.\n\n  * [ Email Alerts ](/shareholder-services/email-alerts \"Email Alerts\")\n  * [ RSS ](/rss \"RSS\")\n  * [ Print page ](javascript:window.print\\(\\); \"Print this Page\")\n  * [ Search ](/search \"Search\")\n\n\n"
        }
      ]
    },
    {
      "section_name": "Events & Presentations",
      "links": [
        {
          "title": "Citi's 2024 Global Healthcare Conference",
          "url": "https://ir.catalystpharma.com/events/event-details/citis-2024-global-healthcare-conference",
          "content": "[Skip to content](#lfg-main-content)\n\n  * [•](https://catalystpharma.com/)\n  * [Follow Us:](#)\n  * [ ![Facebook](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/facebook-xl.png) ](https://www.facebook.com/CatalystForRare)\n  * [ ![Twitter](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/twitter-xl.png) ](https://twitter.com/CatalystForRare)\n  * [ ![Linkedin](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/linkedin-6-xl.png) ](https://www.linkedin.com/company/catalystforrare)\n  * [**Grant Portal**](https://catalystpharma.secure.force.com/fundingrequest/)\n\n\n\n[ ![Catalystpharma.com](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/Catalyst_logo_color.svg) ](https://catalystpharma.com/)\n\nSelect Page\n\n  * [ About Catalyst](http://catalystpharma.com/about-catalyst/)\n    * [History](http://catalystpharma.com/history/)\n    * [Management](http://catalystpharma.com/management/)\n    * [Board Of Directors](http://catalystpharma.com/board-of-directors/)\n    * [Events and Presentations](/events-and-presentations)\n    * [Careers](http://catalystpharma.com/careers/)\n    * [Contact Us](http://catalystpharma.com/contact-us/)\n  * [ Patient Focus](https://catalystpharma.com/patient-focus/)\n    * [ Patient Stories](http://catalystpharma.com/patient-stories/)\n      * [LEMS Stories](http://catalystpharma.com/lems-stories/)\n    * [ Disease Information](http://catalystpharma.com/disease-information/)\n      * [LEMS](http://catalystpharma.com/lems/)\n      * [MuSK-MG](http://catalystpharma.com/musk-mg/)\n      * [Duchenne Muscular Dystrophy (DMD)](https://catalystpharma.com/duchenne-muscular-dystrophy-dmd/)\n    * [ Patient Resources](http://catalystpharma.com/community-engagement/)\n      * [Organizations](https://catalystpharma.com/organizations/)\n      * [Event Calendar](https://catalystpharma.com/event-calendar/)\n      * [Patient Engagement](https://catalystpharma.com/patient-engagement/)\n  * [ Research & Pipeline](http://catalystpharma.com/research-pipeline/)\n    * [Roadmap To Success (Strategy)](http://catalystpharma.com/roadmap-to-success-strategy/)\n    * [ Pipeline (clinical)](http://catalystpharma.com/pipeline-clinical/)\n      * [LEMS Clinical](http://catalystpharma.com/lems-clinical/)\n    * [Business Development](http://catalystpharma.com/business-development/)\n    * [Healthcare Professional Outreach](https://catalystpharma.com/healthcare-professional-outreach/)\n    * [Clinical Trials](https://catalystpharma.com/clinical-trials/)\n  * [ Products](http://catalystpharma.com/amifampridine-phosphate/)\n    * [APPROVED PRODUCTS](https://catalystpharma.com/products/)\n  * [ ESG Responsibility](http://catalystpharma.com/responsibility/)\n    * [Corporate Giving](http://catalystpharma.com/corporate-giving/)\n    * [Investigator Sponsored Research](http://catalystpharma.com/investigator-sponsored-research/)\n    * [ ESG Report](https://catalystpharma.com/responsibility/esg/)\n      * [ESG SASB DISCLOSURE](https://catalystpharma.com/wp-content/uploads/2022/06/Catalyst-SASB-Index_5.25.22_FINAL.pdf)\n  * [ Investors](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-and-presentations)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [ Corporate Governance](/corporate-governance/governance-overview)\n      * [Documents & Charters ](/corporate-governance/governance-overview)\n      * [Board of Directors](https://catalystpharma.com/board-of-directors/)\n      * [Management](https://catalystpharma.com/management/)\n      * [Committee Composition](/corporate-governance/committee-composition)\n      * [Board Diversity Matrix ](/board-diversity-matrix-1)\n      * [Contact the Board](/corporate-governance/governance-contacts)\n    * [ Stock Information](/stock-information)\n      * [Stock Information](/stock-information)\n      * [Historic Stock Lookup](/stock-information/historic-stock-lookup)\n    * [Annual Report and Proxy](/financial-information/annual-reports)\n    * [Analyst Coverage](/financial-information/analyst-coverage)\n    * [Email Alerts](/shareholder-services/email-alerts)\n  * [•](https://catalystpharma.com/)\n  * [Follow Us:](#)\n  * [ ![Facebook](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/facebook-xl.png) ](https://www.facebook.com/CatalystForRare)\n  * [ ![Twitter](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/twitter-xl.png) ](https://twitter.com/CatalystForRare)\n  * [ ![Linkedin](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/linkedin-6-xl.png) ](https://www.linkedin.com/company/catalystforrare)\n  * [**Grant Portal**](https://catalystpharma.secure.force.com/fundingrequest/)\n\n\n\n#  Event Details \n\nInvestor Menu\n\n## Citi's 2024 Global Healthcare Conference \n\n###  Dec 4, 2024 at 1:00 PM EST \n\n[Add to Outlook](/node/16361/ics)\n\n[Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=Catalyst Pharmaceutical - Citi's 2024 Global Healthcare Conference &dates=20241204T180000Z/20241204T180000Z&details=Event Details: https://ir.catalystpharma.com/events/event-details/citis-2024-global-healthcare-conference%0A%0AWebcast: https://kvgo.com/2024-global-healthcare-conference/catalyst-pharmaceuticals-december&location=&trp=false&sprop=&sprop=name:)\n\n[Listen to Webcast](https://kvgo.com/2024-global-healthcare-conference/catalyst-pharmaceuticals-december)\n\n  * [ Email Alerts ](/shareholder-services/email-alerts \"Email Alerts\")\n  * [ RSS ](/rss \"RSS\")\n  * [ Print page ](javascript:window.print\\(\\); \"Print this Page\")\n  * [ Search ](/search \"Search\")\n\n\n"
        },
        {
          "title": "Piper Sandler 36th Annual Healthcare Conference",
          "url": "https://ir.catalystpharma.com/events/event-details/piper-sandler-36th-annual-healthcare-conference",
          "content": "[Skip to content](#lfg-main-content)\n\n  * [•](https://catalystpharma.com/)\n  * [Follow Us:](#)\n  * [ ![Facebook](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/facebook-xl.png) ](https://www.facebook.com/CatalystForRare)\n  * [ ![Twitter](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/twitter-xl.png) ](https://twitter.com/CatalystForRare)\n  * [ ![Linkedin](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/linkedin-6-xl.png) ](https://www.linkedin.com/company/catalystforrare)\n  * [**Grant Portal**](https://catalystpharma.secure.force.com/fundingrequest/)\n\n\n\n[ ![Catalystpharma.com](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/Catalyst_logo_color.svg) ](https://catalystpharma.com/)\n\nSelect Page\n\n  * [ About Catalyst](http://catalystpharma.com/about-catalyst/)\n    * [History](http://catalystpharma.com/history/)\n    * [Management](http://catalystpharma.com/management/)\n    * [Board Of Directors](http://catalystpharma.com/board-of-directors/)\n    * [Events and Presentations](/events-and-presentations)\n    * [Careers](http://catalystpharma.com/careers/)\n    * [Contact Us](http://catalystpharma.com/contact-us/)\n  * [ Patient Focus](https://catalystpharma.com/patient-focus/)\n    * [ Patient Stories](http://catalystpharma.com/patient-stories/)\n      * [LEMS Stories](http://catalystpharma.com/lems-stories/)\n    * [ Disease Information](http://catalystpharma.com/disease-information/)\n      * [LEMS](http://catalystpharma.com/lems/)\n      * [MuSK-MG](http://catalystpharma.com/musk-mg/)\n      * [Duchenne Muscular Dystrophy (DMD)](https://catalystpharma.com/duchenne-muscular-dystrophy-dmd/)\n    * [ Patient Resources](http://catalystpharma.com/community-engagement/)\n      * [Organizations](https://catalystpharma.com/organizations/)\n      * [Event Calendar](https://catalystpharma.com/event-calendar/)\n      * [Patient Engagement](https://catalystpharma.com/patient-engagement/)\n  * [ Research & Pipeline](http://catalystpharma.com/research-pipeline/)\n    * [Roadmap To Success (Strategy)](http://catalystpharma.com/roadmap-to-success-strategy/)\n    * [ Pipeline (clinical)](http://catalystpharma.com/pipeline-clinical/)\n      * [LEMS Clinical](http://catalystpharma.com/lems-clinical/)\n    * [Business Development](http://catalystpharma.com/business-development/)\n    * [Healthcare Professional Outreach](https://catalystpharma.com/healthcare-professional-outreach/)\n    * [Clinical Trials](https://catalystpharma.com/clinical-trials/)\n  * [ Products](http://catalystpharma.com/amifampridine-phosphate/)\n    * [APPROVED PRODUCTS](https://catalystpharma.com/products/)\n  * [ ESG Responsibility](http://catalystpharma.com/responsibility/)\n    * [Corporate Giving](http://catalystpharma.com/corporate-giving/)\n    * [Investigator Sponsored Research](http://catalystpharma.com/investigator-sponsored-research/)\n    * [ ESG Report](https://catalystpharma.com/responsibility/esg/)\n      * [ESG SASB DISCLOSURE](https://catalystpharma.com/wp-content/uploads/2022/06/Catalyst-SASB-Index_5.25.22_FINAL.pdf)\n  * [ Investors](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-and-presentations)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [ Corporate Governance](/corporate-governance/governance-overview)\n      * [Documents & Charters ](/corporate-governance/governance-overview)\n      * [Board of Directors](https://catalystpharma.com/board-of-directors/)\n      * [Management](https://catalystpharma.com/management/)\n      * [Committee Composition](/corporate-governance/committee-composition)\n      * [Board Diversity Matrix ](/board-diversity-matrix-1)\n      * [Contact the Board](/corporate-governance/governance-contacts)\n    * [ Stock Information](/stock-information)\n      * [Stock Information](/stock-information)\n      * [Historic Stock Lookup](/stock-information/historic-stock-lookup)\n    * [Annual Report and Proxy](/financial-information/annual-reports)\n    * [Analyst Coverage](/financial-information/analyst-coverage)\n    * [Email Alerts](/shareholder-services/email-alerts)\n  * [•](https://catalystpharma.com/)\n  * [Follow Us:](#)\n  * [ ![Facebook](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/facebook-xl.png) ](https://www.facebook.com/CatalystForRare)\n  * [ ![Twitter](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/twitter-xl.png) ](https://twitter.com/CatalystForRare)\n  * [ ![Linkedin](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/linkedin-6-xl.png) ](https://www.linkedin.com/company/catalystforrare)\n  * [**Grant Portal**](https://catalystpharma.secure.force.com/fundingrequest/)\n\n\n\n#  Event Details \n\nInvestor Menu\n\n## Piper Sandler 36th Annual Healthcare Conference\n\n###  Dec 3, 2024 at 2:00 PM EST \n\n[Add to Outlook](/node/16356/ics)\n\n[Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=Catalyst Pharmaceutical - Piper Sandler 36th Annual Healthcare Conference&dates=20241203T190000Z/20241203T190000Z&details=Event Details: https://ir.catalystpharma.com/events/event-details/piper-sandler-36th-annual-healthcare-conference%0A%0AWebcast: https://event.webcasts.com/starthere.jsp?ei=1697259&tp_key=471bbf0cf5&location=&trp=false&sprop=&sprop=name:)\n\n[Listen to Webcast](https://event.webcasts.com/starthere.jsp?ei=1697259&tp_key=471bbf0cf5)\n\n  * [ Email Alerts ](/shareholder-services/email-alerts \"Email Alerts\")\n  * [ RSS ](/rss \"RSS\")\n  * [ Print page ](javascript:window.print\\(\\); \"Print this Page\")\n  * [ Search ](/search \"Search\")\n\n\n"
        }
      ]
    },
    {
      "section_name": "Financial Information",
      "links": [
        {
          "title": "Annual Report and Proxy",
          "url": "https://ir.catalystpharma.com/financial-information/annual-reports",
          "content": "[Skip to content](#lfg-main-content)\n\n  * [•](https://catalystpharma.com/)\n  * [Follow Us:](#)\n  * [ ![Facebook](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/facebook-xl.png) ](https://www.facebook.com/CatalystForRare)\n  * [ ![Twitter](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/twitter-xl.png) ](https://twitter.com/CatalystForRare)\n  * [ ![Linkedin](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/linkedin-6-xl.png) ](https://www.linkedin.com/company/catalystforrare)\n  * [**Grant Portal**](https://catalystpharma.secure.force.com/fundingrequest/)\n\n\n\n[ ![Catalystpharma.com](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/Catalyst_logo_color.svg) ](https://catalystpharma.com/)\n\nSelect Page\n\n  * [ About Catalyst](http://catalystpharma.com/about-catalyst/)\n    * [History](http://catalystpharma.com/history/)\n    * [Management](http://catalystpharma.com/management/)\n    * [Board Of Directors](http://catalystpharma.com/board-of-directors/)\n    * [Events and Presentations](/events-and-presentations)\n    * [Careers](http://catalystpharma.com/careers/)\n    * [Contact Us](http://catalystpharma.com/contact-us/)\n  * [ Patient Focus](https://catalystpharma.com/patient-focus/)\n    * [ Patient Stories](http://catalystpharma.com/patient-stories/)\n      * [LEMS Stories](http://catalystpharma.com/lems-stories/)\n    * [ Disease Information](http://catalystpharma.com/disease-information/)\n      * [LEMS](http://catalystpharma.com/lems/)\n      * [MuSK-MG](http://catalystpharma.com/musk-mg/)\n      * [Duchenne Muscular Dystrophy (DMD)](https://catalystpharma.com/duchenne-muscular-dystrophy-dmd/)\n    * [ Patient Resources](http://catalystpharma.com/community-engagement/)\n      * [Organizations](https://catalystpharma.com/organizations/)\n      * [Event Calendar](https://catalystpharma.com/event-calendar/)\n      * [Patient Engagement](https://catalystpharma.com/patient-engagement/)\n  * [ Research & Pipeline](http://catalystpharma.com/research-pipeline/)\n    * [Roadmap To Success (Strategy)](http://catalystpharma.com/roadmap-to-success-strategy/)\n    * [ Pipeline (clinical)](http://catalystpharma.com/pipeline-clinical/)\n      * [LEMS Clinical](http://catalystpharma.com/lems-clinical/)\n    * [Business Development](http://catalystpharma.com/business-development/)\n    * [Healthcare Professional Outreach](https://catalystpharma.com/healthcare-professional-outreach/)\n    * [Clinical Trials](https://catalystpharma.com/clinical-trials/)\n  * [ Products](http://catalystpharma.com/amifampridine-phosphate/)\n    * [APPROVED PRODUCTS](https://catalystpharma.com/products/)\n  * [ ESG Responsibility](http://catalystpharma.com/responsibility/)\n    * [Corporate Giving](http://catalystpharma.com/corporate-giving/)\n    * [Investigator Sponsored Research](http://catalystpharma.com/investigator-sponsored-research/)\n    * [ ESG Report](https://catalystpharma.com/responsibility/esg/)\n      * [ESG SASB DISCLOSURE](https://catalystpharma.com/wp-content/uploads/2022/06/Catalyst-SASB-Index_5.25.22_FINAL.pdf)\n  * [ Investors](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-and-presentations)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [ Corporate Governance](/corporate-governance/governance-overview)\n      * [Documents & Charters ](/corporate-governance/governance-overview)\n      * [Board of Directors](https://catalystpharma.com/board-of-directors/)\n      * [Management](https://catalystpharma.com/management/)\n      * [Committee Composition](/corporate-governance/committee-composition)\n      * [Board Diversity Matrix ](/board-diversity-matrix-1)\n      * [Contact the Board](/corporate-governance/governance-contacts)\n    * [ Stock Information](/stock-information)\n      * [Stock Information](/stock-information)\n      * [Historic Stock Lookup](/stock-information/historic-stock-lookup)\n    * [Annual Report and Proxy](/financial-information/annual-reports)\n    * [Analyst Coverage](/financial-information/analyst-coverage)\n    * [Email Alerts](/shareholder-services/email-alerts)\n  * [•](https://catalystpharma.com/)\n  * [Follow Us:](#)\n  * [ ![Facebook](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/facebook-xl.png) ](https://www.facebook.com/CatalystForRare)\n  * [ ![Twitter](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/twitter-xl.png) ](https://twitter.com/CatalystForRare)\n  * [ ![Linkedin](/sites/g/files/knoqqb26556/themes/site/nir_pid2370/dist/images/linkedin-6-xl.png) ](https://www.linkedin.com/company/catalystforrare)\n  * [**Grant Portal**](https://catalystpharma.secure.force.com/fundingrequest/)\n\n\n\n#  Annual Report and Proxy \n\nInvestor Menu\n\n##  Annual Reports \n\n[2023 Annual Report](/static-files/437d3d90-54cf-4adf-9ccb-e8feb009ac1f \"2023 Catalyst Pharmaceuticals Annual Report.pdf\") 2.5 MB\n\n[2022 Annual Report](/static-files/0ca6a0ec-d104-414f-ba6b-76cd5ec45e89 \"2022 Catalyst Pharmaceuticals Annual Report.pdf\") 3.3 MB\n\n[2021 Annual Report](/static-files/e20608ac-9c57-4cc7-8c5b-e1c8cc1d447b \"Catalyst 2021 Annual Report.pdf\") 2.6 MB\n\n[2020 Annual Report](/static-files/9207b047-a318-444c-b395-60336395cbdf \"Catalyst AR2020.compiled.pdf\") 3.2 MB\n\n[2019 Annual Report](/static-files/8ae3a6b7-9902-4821-b271-b5bb4eece4b7 \"Catalyst 2019AR.compiled.pdf\") 1.9 MB\n\n##  Proxy Statement \n\n[2024 Proxy Statement](/static-files/24396e13-6852-4ef4-95ef-5b5165fa7252 \"2024 Catalyst Pharmaceuticals Proxy.pdf\") 1.1 MB\n\n  * [ Email Alerts ](/shareholder-services/email-alerts \"Email Alerts\")\n  * [ RSS ](/rss \"RSS\")\n  * [ Print page ](javascript:window.print\\(\\); \"Print this Page\")\n  * [ Search ](/search \"Search\")\n\n\n"
        }
      ]
    }
  ]
}